Protective effects of melatonin against thioacetamide-induced liver fibrosis in rats

Journal of Physiology and Pharmacology

Volumn 66, Issue 4, 2015, Pages 567-579

  Czechowska, G ^a   Celinski, Krzysztof ^a   Korolczuk, A ^a   Wojcicka, G ^a   Dudka, J ^a   Bojarska, A ^b   Reiter, R J ^c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Medical University of Lublin   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Fibrosis; Inflammatory cytokines; Liver; Melatonin; Oxidative stress; Paraoxon; Paraoxonase 1; Phenyl acetate

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ASPARTATE AMINOTRANSFERASE; CYTOKINE; INTERLEUKIN 6; MELATONIN; MESSENGER RNA; PARAOXON; TUMOR NECROSIS FACTOR ALPHA; ARYLDIALKYLPHOSPHATASE; THIOACETAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BONE REMODELING; CONTROLLED STUDY; ENZYME ACTIVITY; HEMATOPOIESIS; HISTOPATHOLOGY; HOMEOSTASIS; METABOLIC REGULATION; MOLECULAR BIOLOGY; NONHUMAN; OXIDATIVE STRESS; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; THIOACETAMIDE-INDUCED LIVER FIBROSIS; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CYTOKINES; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MELATONIN; OXIDATIVE STRESS; RATS; RATS, WISTAR; THIOACETAMIDE;

EID: 84940784003     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218.
2. Bonis PA, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2001; 344: 452-454.
3. Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004; 40: 860-867.
4. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013; 5: 167sr1.
5. Konturek SJ, Konturek PC, Brzozowski T, Bubenik GA. Role of melatonin in upper gastrointestinal tract. J Physiol Pharmacol 2007; 58 (Suppl. 6): 23-52.
6. Gulcin I, Buyukokuroglu ME, Kufrevioglu O. Metal chelating and hydrogen peroxide scavenging effects of melatonin. J Pineal Res 2003; 34: 278-281.
7. Tahan V, Ozaras R O, Canbakan B, et al. Melatonin reduces dimethylnitrosamine-induced liver fibrosis. J Pineal Res 2004; 37: 78-84.
8. Lahiri S, Singh P, Singh S, Rasheed N, Palit G, Pant KK. Melatonin protects against experimental reflux esophagitis. J Pineal Res 2009; 46: 207-213.
9. Sidhu S, Pandhi P, Malhotra S, Vaiphei K, Khanduja KL. Melatonin treatment is beneficial in pancreatic repair process after experimental acute pancreatitis. Eur J Pharmacol 2010; 628: 282-289.
10. Reiter RJ, Tan DX, Manchester LC, Pilar Terron M, Flores LJ, Koppisepi S. Medical implications of melatonin: receptor-mediated and receptor independent actions. Adv Med Sci 2007; 52: 11-28.
11. Jaworek J, Konturek SJ, Leja-Szpak A, et al. Role of endogenous melatonin and its MT2 receptor in the modulation of caerulein-induced pancreatitis in the rat. J Physiol harmacol 2002; 53: 791-804.
12. Konturek SJ, Zayachkivska O, Havryluk XO, et al. Protective influence of melatonin against acute esophageal lesions involves prostaglandins, nitric oxide and sensory nerves. J Physiol Pharmacol 2007; 58: 361-377.
13. Barchas J, Da Costa F, Spector S. Acute pharmacology of melatonin. Nature 1967; 214: 919-920.
14. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 330-335.
15. Lowry OH, Rosenbrough NJ, Farr AJ, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
16. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
17. Tahan V, Artug O, Akin H, et al. Melatonin ameliorates methionine choline deficient diet induced nonalcoholic steatohepatitis in rats. J Pineal Res 2009; 46: 401-407.
18. Muller D, Sommer M, Kretzschmar M, et al. Lipid peroxidation on thioacetamide-induced macronodular cirrhosis. Arch Toxicol 1991; 65: 199-203.
19. Abul H, Mathew TC, Dashti HM, Al-Bader A. Level of superoxide dismutase, glutathione peroxidase and uric acid in thioacetamide-induced cirrhotic rats. Anat Histol Embryol 2002; 31: 66-71.
20. Friedman SL. Mechanism of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
21. Henderson NC, Forbes SJ. Hepatic fibrogenesis: from within and outwith. Toxicology2008; 254: 130-135.
22. Kus J, Ogeturk M, Oner H, Sahin S, Yekeler H, Sarsilmaz M. Protective effects of melatonin against carbon tetrachloride-induced hepatotoxicity in rats: a light microscopic and biochemical study. CellBiochem Funct 2005; 23: 169-174.
23. Fierbinteanu-Braticevici C, Negreanu L, Tarantino G. Is fatty liver always benign and should not consequently be treated? J Physiol Pharmacol 2013; 64: 3-9.
24. Gonciarz M, Gonciarz Z, Bielanski W, et al. The effect of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipid and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J Physiol Pharmacol 2012; 63: 35-40.
25. Celinski K, Konturek PC, Slomka M, et al. Altered basal and postprandial plasma melatonin, gastrin, ghrelin, leptin and insulin in patients with liver cirrhosis and portal hypertension without and with oral administration of melatonin or tryptophan. J Pineal Res 2009; 46: 408-414.
26. Celinski K, Konturek PC, Slomka M, et al. Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease - 14 months follow up. J Physiol Pharmacol 2014; 65: 75-82.
27. Wang H, Wei W, Wang NP, et al. Melatonin ameliorates carbon tetrachloride-induced hepatic fibrogenesis in rats via inhibition of oxidative stress. Life Sci 2005; 77: 1902-1915.
28. Hong RT, Xu JM, Mei Q. Melatonin ameliorates experimental hepatic fibrosis induced by carbon tetrachloride in rats. World J Gastroenterol 2009; 15: 1452-1460.
29. Aranda M, Albendea CD, Lostale F, et al. In vivo hepatic oxidative stress because of carbon tetrachloride toxicity: protection by melatonin and pinoline. J Pineal Res2010; 49:78-85.
30. Montilla P, Cruz A, Padillo FJ, et al. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats. J Pineal Res 2001; 31: 138-144.
31. Manda K, Bhatia AL. Prophylactic action of melatonin for cyclophosphamide-induced oxidative stress in mice. Cell Biol Toxicol 2003; 19: 367-372.
32. Sigala F, Theocharis S, Sigalas K, et al. Therapeutic value of melatonin in an experimental model of liver injury and regeneration. J Pineal Res 2006; 40: 270-279.
33. Cruz A, Padillo FJ, Torres E, et al. Melatonin prevents experimental liver cirrhosis induced by thioacetamide in rats. J Pineal Res 2005; 39: 143-150.
34. Schwabe RF, Brenner DA. Mechanisms of liver injury. TNF-alfa-induced liver injury: role of IKK, JNK and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006; 290: 583-589.
35. Wei YH, Jun L, Qiang CJ. Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCL4 in rats. Dig Dis Sci 2004; 49:1589-1594.
36. Bayer EM, Herr W, Kanzler S, et al. Transforming growth factor beta-1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J Hepatol 1998; 28: 803-811.
37. Marsillach J, Aragones G, Mackness M, et al. Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids Health Dis 2010; 9: 46.
38. Marsillach J, Camps J, Ferre N, et al. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterol 2009; 9: 3.
39. Ferre N, Camps J, Prats E, et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002; 48: 261-268.
40. Kedage V, Mutigi MS, Shetty MS, et al. Serum paraoksonase1 activity status in patients with liver disorders. Saudi J Gastroenterol 2010; 16: 79-83.